Harpoon Therapeutics assumed with a Buy at Canaccord

• Canaccord analyst William Maughan assumed coverage of Harpoon Therapeutics (HARP) with a Buy rating and $16 price target.
• Bispecific T-cell engagers, like the ones Harpoon is developing, are "among the hottest therapeutic strategies in development for oncology," said Maughan, who adds that Harpoon has been "a pioneer in the field."
• He thinks recent memory of setbacks and a financing overhang are keeping investors on the sidelines, but he argues that the Harpoon platform "remains solid."
• Harpoon Therapeutics's SA Quant Rating stands with a Strong Sell whereas, Wall St. Analysts Rating says Strong Buy (7 Very Bullish, 2 Bullish).
• Since the start of 2022, Harpoon Therapeutics's shares were down around 75%, and over a period of one year, shares were down around 85%.
• Shares are currently +0.5% to $2.03 today.